Journal Article
. 2011 Jan;1().
doi: 10.3389/fonc.2011.00012.

The implications of breast cancer molecular phenotype for radiation oncology

Shirin Sioshansi 1 Kathryn E Huber  David E Wazer  
Affiliations
  • PMID: 22649753
  •     50 References
  •     5 citations

Abstract

The identification of distinct molecular subtypes of breast cancer has advanced the understanding and treatment of breast cancer by providing insight into prognosis, patterns of recurrence, and effectiveness of therapy. The prognostic significance of molecular phenotype with regard to distant recurrences and overall survival are well established in the literature and has been readily incorporated into systemic therapy management decisions. However, despite the accumulating data suggesting similar prognostic significance for locoregional recurrence, integration of molecular phenotype into local management decision making has lagged. Although there are some conflicting reports, collectively the literature supports a low risk of local recurrence (LR) in the hormone receptor (HR) positive luminal subtypes compared to HR negative subtypes [triple negative (TN) and HER2-enriched]. The development of targeted therapies, such as trastuzumab for the treatment of HER2-enriched subtype, has been shown to mitigate the increased risk of LR. Unfortunately, no such remedy exists to address the increased risk of LR for patients with TN tumors, making it a clinical challenge for radiation oncologists. In this review we discuss the correlation between molecular subtype and LR following either breast conservation therapy or mastectomy. We also explore the possible mechanisms for increased LR in TN breast cancer and radiotherapeutic implications for this population, such as the safety of breast conservation, consideration of dose escalation, and the appropriateness of accelerated partial breast irradiation.

Keywords: breast; cancer; local; negative; radiotherapy; recurrence; subtype; triple.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast.
Henry M Kuerer, Aman U Buzdar, +7 authors, William Fraser Symmans.
Cancer, 2010 Aug 27; 117(1). PMID: 20740500    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Identification of patients who are at high risk for locoregional breast cancer recurrence after conservative surgery and radiotherapy: a review article for surgeons, pathologists, and radiation and medical oncologists.
D H Clarke, A A Martinez.
J Clin Oncol, 1992 Mar 01; 10(3). PMID: 1311027
Review.
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Torsten O Nielsen, Forrest D Hsu, +13 authors, Charles M Perou.
Clin Cancer Res, 2004 Aug 26; 10(16). PMID: 15328174
Highly Cited.
Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, +7 authors, Steven A Narod.
Clin Cancer Res, 2007 Aug 03; 13(15 Pt 1). PMID: 17671126
Highly Cited.
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial.
Heather A Jones, Ninja Antonini, +13 authors, Harry Bartelink.
J Clin Oncol, 2009 Sep 02; 27(30). PMID: 19720914    Free PMC article.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
Therese Sørlie.
Eur J Cancer, 2004 Dec 02; 40(18). PMID: 15571950
Review.
Five-year outcome of patients classified in the "unsuitable" category using the American Society of Therapeutic Radiology and Oncology (ASTRO) Consensus Panel guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite® Registry trial.
Peter Beitsch, Frank Vicini, +3 authors, Maureen Lyden.
Ann Surg Oncol, 2010 Oct 01; 17 Suppl 3. PMID: 20853036
Concordance among gene-expression-based predictors for breast cancer.
Cheng Fan, Daniel S Oh, +5 authors, Charles M Perou.
N Engl J Med, 2006 Aug 11; 355(6). PMID: 16899776
Highly Cited.
Outcomes of breast cancer patients with triple negative receptor status treated with accelerated partial breast irradiation.
J Ben Wilkinson, Robert E Reid, +7 authors, Frank A Vicini.
Int J Radiat Oncol Biol Phys, 2011 Feb 25; 81(3). PMID: 21345613
Outcomes after accelerated partial breast irradiation in patients with ASTRO consensus statement cautionary features.
Derek R McHaffie, Rakesh R Patel, +3 authors, George M Cannon.
Int J Radiat Oncol Biol Phys, 2010 Aug 25; 81(1). PMID: 20732760
Factors influencing cosmetic results after conservation therapy for breast cancer.
M E Taylor, C A Perez, +7 authors, C Rush.
Int J Radiat Oncol Biol Phys, 1995 Feb 15; 31(4). PMID: 7860386
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Marianne Kyndi, Flemming B Sørensen, +4 authors, Danish Breast Cancer Cooperative Group.
J Clin Oncol, 2008 Feb 21; 26(9). PMID: 18285604
Highly Cited.
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, +3 authors, W L McGuire.
Science, 1987 Jan 09; 235(4785). PMID: 3798106
Highly Cited.
The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Dennis B Cornfield, Juan P Palazzo, +5 authors, Roland Schwarting.
Cancer, 2004 May 26; 100(11). PMID: 15160334
Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Ewan K A Millar, Peter H Graham, +13 authors, Robert L Sutherland.
J Clin Oncol, 2009 Sep 02; 27(28). PMID: 19720911
Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
Christos Sotiriou, Soek-Ying Neo, +7 authors, Edison T Liu.
Proc Natl Acad Sci U S A, 2003 Aug 15; 100(18). PMID: 12917485    Free PMC article.
Highly Cited.
Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial.
Harry Bartelink, Jean-Claude Horiot, +9 authors, Laurence Collette.
J Clin Oncol, 2007 Jun 20; 25(22). PMID: 17577015
Highly Cited.
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, +13 authors, David Botstein.
Proc Natl Acad Sci U S A, 2003 Jun 28; 100(14). PMID: 12829800    Free PMC article.
Highly Cited.
Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status.
Richard B Wilder, Lisa D Curcio, +9 authors, Kenneth M Tokita.
Int J Radiat Oncol Biol Phys, 2010 Sep 28; 78(3). PMID: 20869583
Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
B Fisher, C Redmond, +7 authors, J Wittliff.
J Clin Oncol, 1983 Apr 01; 1(4). PMID: 6366135
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Epidemiology of basal-like breast cancer.
Robert C Millikan, Beth Newman, +13 authors, Charles M Perou.
Breast Cancer Res Treat, 2007 Jun 21; 109(1). PMID: 17578664    Free PMC article.
Highly Cited.
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
M Overgaard, M B Jensen, +9 authors, H T Mouridsen.
Lancet, 1999 May 21; 353(9165). PMID: 10335782
Highly Cited.
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Katrina R Bauer, Monica Brown, +2 authors, Vincent Caggiano.
Cancer, 2007 Mar 28; 109(9). PMID: 17387718
Highly Cited.
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
Eleftherios P Mamounas, Gong Tang, +7 authors, Norman Wolmark.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065188    Free PMC article.
Highly Cited.
Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation.
Gary M Freedman, Penny R Anderson, Tianyu Li, Nicos Nicolaou.
Cancer, 2009 Jan 22; 115(5). PMID: 19156929    Free PMC article.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO).
Benjamin D Smith, Douglas W Arthur, +11 authors, Jay R Harris.
Int J Radiat Oncol Biol Phys, 2009 Jun 24; 74(4). PMID: 19545784
Highly Cited.
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.
Bruce G Haffty, Qifeng Yang, +6 authors, Deborah Toppmeyer.
J Clin Oncol, 2006 Nov 23; 24(36). PMID: 17116942
Highly Cited.
Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer.
Jeffrey M Albert, Ana M Gonzalez-Angulo, +8 authors, Thomas A Buchholz.
Int J Radiat Oncol Biol Phys, 2010 May 18; 77(5). PMID: 20472353
Breast cancer subtypes and the risk of local and regional relapse.
K David Voduc, Maggie C U Cheang, +3 authors, Hagen Kennecke.
J Clin Oncol, 2010 Mar 03; 28(10). PMID: 20194857
Highly Cited.
Reconstructive surgery in young women with breast cancer.
Martina Marín-Gutzke, Alberto Sánchez-Olaso.
Breast Cancer Res Treat, 2010 Aug 20; 123 Suppl 1. PMID: 20721689
Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer.
Simon J Crabb, Maggie C U Cheang, +5 authors, Stephen K Chia.
Clin Breast Cancer, 2008 Jul 25; 8(3). PMID: 18650155
High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c.
Marianne Kyndi, Marie Overgaard, +3 authors, Jens Overgaard.
Radiother Oncol, 2008 May 13; 90(1). PMID: 18471914
Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status.
William D Foulkes, Matthew J Grainge, +2 authors, Ian O Ellis.
Breast Cancer Res Treat, 2008 Jul 05; 117(1). PMID: 18600446
Does race affect outcomes in triple negative breast cancer?
Jasgit C Sachdev, Saira Ahmed, +3 authors, Mohammad Jahanzeb.
Breast Cancer (Auckl), 2010 Aug 11; 4. PMID: 20697530    Free PMC article.
Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
Wenjing Zhou, Karin Jirström, +4 authors, Fredrik Wärnberg.
BMC Cancer, 2010 Dec 02; 10. PMID: 21118480    Free PMC article.
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Paul L Nguyen, Alphonse G Taghian, +7 authors, Jay R Harris.
J Clin Oncol, 2008 Apr 17; 26(14). PMID: 18413639
Highly Cited.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Triple-negative breast cancers: unique clinical presentations and outcomes.
Julie A Y Billar, Amylou C Dueck, +5 authors, Barbara A Pockaj.
Ann Surg Oncol, 2010 Oct 01; 17 Suppl 3. PMID: 20853062
Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ.
Rodica Stackievicz, Haim Paran, +5 authors, Mordechai Gutman.
Isr Med Assoc J, 2010 Oct 12; 12(5). PMID: 20929083
Mammographic breast density: effect on imaging and breast cancer risk.
Renee W Pinsky, Mark A Helvie.
J Natl Compr Canc Netw, 2010 Oct 26; 8(10). PMID: 20971840
Review.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
Martine J Piccart-Gebhart, Marion Procter, +30 authors, Herceptin Adjuvant (HERA) Trial Study Team.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236737
Highly Cited.
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
M Overgaard, P S Hansen, +8 authors, K Zedeler.
N Engl J Med, 1998 Feb 12; 337(14). PMID: 9395428
Highly Cited.
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Maggie C U Cheang, David Voduc, +5 authors, Torsten O Nielsen.
Clin Cancer Res, 2008 Mar 05; 14(5). PMID: 18316557
Highly Cited.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, +14 authors, Robert C Millikan.
JAMA, 2006 Jun 08; 295(21). PMID: 16757721
Highly Cited.
Number of negative lymph nodes can predict survival after postmastectomy radiotherapy according to different breast cancer subtypes.
San-Gang Wu, Fang Peng, +6 authors, Zhen-Yu He.
J Cancer, 2015 Feb 11; 6(3). PMID: 25663944    Free PMC article.
Carbon ion beam combined with cisplatin effectively disrupts triple negative breast cancer stem-like cells in vitro.
Sei Sai, Guillaume Vares, +5 authors, Mitsuhiro Hayashi.
Mol Cancer, 2015 Sep 05; 14. PMID: 26338199    Free PMC article.
Being Overweight or Obese Increases the Risk of Progression in Triple-Negative Breast Cancer after Surgical Resection.
Yunseon Choi, Sung Kwang Park, +4 authors, Yun-Han Lee.
J Korean Med Sci, 2016 Jun 02; 31(6). PMID: 27247497    Free PMC article.
Combination of carbon-ion beam and dual tyrosine kinase inhibitor, lapatinib, effectively destroys HER2 positive breast cancer stem-like cells.
Sei Sai, Eun Ho Kim, +4 authors, Mitsuhiro Hayashi.
Am J Cancer Res, 2020 Sep 10; 10(8). PMID: 32905515    Free PMC article.
Local Disease-Free Survival Rate (LSR) Application to Personalize Radiation Therapy Treatments in Breast Cancer Models.
Gaetano Savoca, Marco Calvaruso, +8 authors, Giorgio Russo.
J Pers Med, 2020 Oct 22; 10(4). PMID: 33080870    Free PMC article.